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Background We examined the relationship between timing and duration of folic acid (FA) supplementation in achieving red blood cell (RBC)
folate levels in early pregnancy which are optimal (>906 nmol/l) for the prevention of neural tube defects (NTDs).
Methods Clinical, FA supplementation and dietary folate details were computerized at the ﬁrst antenatal visit. Maternal blood samples were
analysed for RBC and serum folate.
Results Of the 502 women, 98.2% (n = 493) reported taking FA. There was a positive correlation between duration of supplementation and both
RBC folate (r = 0.43, P < 0.001) and serum folate (rho = 0.29, P < 0.001). The optimal RBC folate level was achieved in 80.4% (n = 46) of women who
started FA 400 μg 4–8 weeks before their LMP compared with only 53.6% (n = 153) in women who started 4–8 weeks after their LMP (P < 0.001).
Conclusions This study provides, for the ﬁrst time, information on both the timing and duration of FA that will achieve the optimum RBC
folate levels associated with the prevention of NTDs. Women who are taking FA (400 μg) need to start before they conceive.
Keywords dietary folate, food fortiﬁcation, neural tube defects, folic acid supplements, red blood cell folate, serum folate

Introduction
Neural tube defects (NTDs) are a group of serious congenital neurodevelopmental malformations which carry a heavy
burden of illness.1,2 Evidence that they may be prevented by
folic acid (FA) comes from two landmark randomized controlled trials (RCT).3,4 Subsequently, national guidelines published after 1992 recommended periconceptional FA
supplementation to prevent both the occurrence and the
recurrence of NTDs.5,6 This supplementation strategy has,
however, made little impact on NTD rates worldwide.1,7
Thus, since 1998 a growing number of countries have implemented a policy of mandatory food fortiﬁcation with FA.2,7
One meta-analysis estimated that mandatory FA fortiﬁcation
halves the incidence of NTDs nationally.8
In 2006, the Food Safety Authority of Ireland (FSAI)
recommended mandatory fortiﬁcation of bread with FA.9,10

However, 2 years later the FSAI recommended deferral
because an unpublished survey suggested NTD rates were
falling nationally, voluntary folate fortiﬁcation levels had
increased and there were theoretical concerns about the
impact of fortiﬁcation on rates of colonic cancer.9,10 Recent
European studies found that the levels of voluntary food
fortiﬁcation with FA have declined and that the prevalence
of NTDs is not decreasing.1,7,11 This led to an updated
report from the FSAI in 2016 recommending mandatory
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fortiﬁcation as an option for preventing NTDs.12 There
have also been renewed calls in the UK for mandatory food
fortiﬁcation with folate.13
In this study we examined the relationship between the
timing and duration of FA supplementation on both maternal serum and RBC folate levels amongst women presenting
for antenatal care in early pregnancy, in a country where
food FA fortiﬁcation remains voluntary.

Separation of serum

Methods

Appropriately diluted serum and whole-blood haemolysate
was then added to an assay medium containing Lactobacillus
casei in addition to all nutrients needed for the growth of L.
casei except folate. This method has been previously
described in detail and is the recognized gold-standard for
serum and RBC folate estimation.14 This inoculated medium
was incubated for 42 h at 37°C, and total folate was then
assessed by measuring the turbidity of the inoculated
medium at 590 nmol/l in a microplate reader.
For the assessment of RBC folate, the measured wholeblood value is related to the measured Hct according to the
following equation:

Red blood cell folate

A 1% solution of ascorbic acid was freshly prepared and
900 μl of this solution was aliquoted into each of two
labelled 2 ml plastic tubes. The whole-blood was mixed carefully. A 100 μl of this whole-blood was added to each of the
tubes containing the 900 μl of 1% ascorbic acid solution.
The contents of these tubes were mixed well by pipetting up
and down. The whole-blood/ascorbic acid mixture was left
at room temperature for 30 min so that endogenous serum
folate conjugase could convert folate polyglutamates released
from the lysed red cells to the assayable monoglutamate
form. These ascorbic acid lysates were then stored at −40°C
pending further analysis.

Red blood cell and serum folate microbiological
assays

RBC folateðnmol=lÞ ¼ ðWhole blood hemolysate folate ∗ 10Þ
− Serum folateð1 − Hct=100Þ=Hct=100

A detailed questionnaire about all supplement intakes was
completed under the supervision of a research dietitian (S.C.).
Daily compliance with FA supplement use was assessed by
asking the woman how many days per week she took a FA
supplement and also how many tablets per day she consumed. To collect estimated habitual food intakes for analysis
of total dietary folate (natural folate and synthetic FA from
fortiﬁed foods) women were asked to complete a retrospective 4-day diet history (DH) under supervision. This was combined with a customized food frequency questionnaire (FFQ)
to capture the brand names of foods fortiﬁed with FA
because in Ireland, FA is added to food on a voluntary basis
and the amount added varies according to the brand. This
method of dietary data collection has previously been validated for the collection and calculation of dietary folate
intake.15 Assessment of energy under- and over-reporting was
calculated using standard equations for females.16,17
Quantitative food intake data from the 4-day DH was
divided by four to get an average daily intake for each food
listed. These data were entered into Nutritics Version 3.7 to
convert the reported food intakes into nutrient intakes derived
from these foods.18 Food recipes for foods not included in
the existing databases of Nutritics (e.g. branded foods which
have been fortiﬁed with FA such as breads, spreads, cereals,
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The Hospital is one of the largest maternity hospitals in
Europe and cares for women from all socioeconomic
groups and from across the urban–rural divide. Women
were recruited at their convenience at their ﬁrst antenatal
visit between June 2014 and March 2016 after sonographic
conﬁrmation of an ongoing singleton pregnancy. Exclusion
criteria were multiple pregnancies, a history of a previous
NTD or an inability to understand English. Informed written consent was obtained. Women’s clinical and sociodemographic details were computerized routinely and updated
immediately after delivery.
Once consent was obtained, at the time of taking the routine ﬁrst visit blood tests, two additional samples were taken.
These samples were transported in a cool box within 4 h of
extraction for separation, storage at −70°C and analysis.14
On receipt of the 2.7 ml serum tube in the laboratory, this
tube was left to sit for ~30 min, to allow the clot to settle.
The clot was removed from the tube and the tube recapped.
This was centrifuged at 2200 revolutions per minute (rpm)
for 10 min, and the serum was drawn off and stored in
duplicate.
The 7.5 ml EDTA tube was placed on the blood mixer
for 10 min. Haematocrit (Hct) was measured on the
Hawksley Micro-Haematocrit Reader.

The blood in the clotting blood tubes was centrifuged to
yield a pellet and a clear supernatant. The centrifuge may or
may not be refrigerated. The separated serum was aspirated
carefully from the packed cells and aliquoted into duplicate
labelled plastic tubes.

OPTIMIZATION OF FOLIC ACID SUPPLEMENTATION

Results
All 502 women had their serum and RBC folate levels measured. Of these, 458 women completed the detailed FA supplement questionnaire. For the remaining 44 (8.8%) women
who did not have time to complete this questionnaire, additional information on FA supplementation was obtained
from their medical records. These data described the dose
of FA used and whether FA supplementation had started
before pregnancy or not. Of the 458 women who completed
the detailed FA supplement questionnaire, only 437 reported
the time of initiation of FA.

Of the 502 women, 493 (98.2%) reported taking FA during the pregnancy. Of the 493 women, 447 women reported
on their compliance with 93.9% reporting daily intake of FA.
Of the women who knew the dose or brand of FA that they
were taking at presentation (n = 440), 1.1% (n = 5) were taking <400 μg FA/day, 91.8% (n = 404) were taking 400 μg
FA/day and 7.0% (n = 31) were taking >400 μg FA/day.
The characteristics of the study population are shown in
Table 1 and were similar to the hospital population.20 None
of the pregnancies were complicated by a NTD. The women
who initiated FA supplementation before pregnancy were
compared with those who did not using univariate analysis
(Table 1). Binary logistic regression analysis was applied to
adjust for the other putative predictors of prepregnancy FA
supplementation which had emerged on univariate analyses
(age, pregnancy intention, marital status, smoking status and
third level education (deﬁned as third level non-degree qualiﬁcation (e.g. diploma) or higher)). Those who planned their
pregnancy and who had third level education were more
likely to take FA before their LMP (odds ratio (OR) = 9.1
(95% CI: 5.2–15.6); P < 0.001 and OR = 2.3 (95% CI:
1.4–3.8); P < 0.001, respectively) in these multivariate analyses. Those who were self-reported smokers were less likely
to take FA before their LMP (OR = 0.18 (95% CI: 0.1–0.5);
P < 0.001) on multivariate analysis. The results of the multivariate analysis is now shown in greater detail within
Supplementary Table 1.
Table 2 shows the timing of FA supplementation initiation
in relation to the LMP in bands of 4 weeks. Of the 458
women who completed the detailed FA questionnaire, 437
provided details about when they initiated FA supplement
use. The majority (56%) of women did not initiate FA until
after their LMP (Supplementary Figures 2 and 3). Initiation
after the LMP was clustered in the 4–8 weeks interval.
Supplementary Figure 4 shows timing of women’s initiation
of FA (n = 437) according to whether they had planned their
pregnancy; 89% (n = 170) of women who started FA before
their LMP (n = 192) had planned their pregnancy compared
with 43.2% (n = 106) who started after their LMP (n = 245)
(P < 0.001). It is clear from Supplementary Figure 5 that the
percentage of unplanned pregnancy increased moving from
left to right on the bar chart.
Supplementary Figure 1 shows when women started FA
during the pregnancy.
In Tables 3 and 4, the time interval 4–8 weeks after the
ﬁrst day of the LMP has been used as the reference for
comparison with other time intervals for FA supplement
commencement (In this interval the majority of women who
are not taking FA before the pregnancy start to take FA
(Supplementary Table 1).
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cereal bars and fortiﬁed milks) were manually generated to
accurately capture nutrient intakes. Information on socioeconomic status was assessed using questions from the EU
Survey on Income and Living Conditions.19
Data from all questionnaires were anonymised and coded
on a Microsoft Excel® spreadsheet and statistical analysis was
conducted using SPSS for Windows, Version 20 (IBM
Corporation, Armonk, New York). The distribution of continuous data was assessed for normality. Descriptive statistics
were ﬁrst used to characterize the study cohort. One-way
ANOVA and independent-samples t-tests were used to compare mean RBC folate levels according to the time of FA supplement initiation, as these data were normally distributed.
Inferential Chi-square tests for independence were then used
to analyse differences in categorical variables (e.g. achieving
optimal RBC folate level for NTD prevention) between different population groups.
Kruskal–Wallis and Mann–Whitney U tests were used to
compare median dietary folate intakes and median serum
folate levels according to time of FA supplement initiation
as data from these variables were non-normally distributed.
Binary logistic regression analysis was ﬁnally performed to
assess the independent associations between a number of
putative predictor variables and the likelihood of supplementing with FA prior to pregnancy. Factors were included
in the multivariate model based on a statistically signiﬁcant
ﬁnding from previous mutually adjusted univariate analyses
examining preconceptional FA supplementation (P < 0.05).
The time interval 4–8 weeks after the ﬁrst day of the last
menstrual period (LMP) has been used as the reference for
comparison with other time intervals for FA supplement
commencement. This interval includes the time around 5–6
weeks amenorrhoea when pregnancy is usually conﬁrmed by
a positive urinary human chorionic gonadotropin (HCG)
test. Also, in this interval, women who are not taking FA
supplements before pregnancy usually start FA and the
neural tube closes (Supplementary Figure 1).

829

830

JOURNAL OF PUBLIC HEALTH

Table 1 Univariate analysis of sociodemographic characteristics of participants analysed according to whether they initiated folic acid (FA)
supplementation before or after their last menstrual period (LMP) (n = 502)
Total (n = 502)

Prepregnancy supplementationa (n = 215)

Pregnancy supplementationb (n = 287)

P

30.6 (5.5)

32.2 (4.3)

29.5 (6.0)

<0.001

67.5 (17.40)

67.5 (17.2)

67.4 (18.3)

0.35

Body Mass Index [kg/m2; median (IQR)]

24.7(5.9)

24.7 (5.6)

24.7 (6.2)

0.66

Obese [%; n]

19.3 (97)

20.0 (43)

18.8 (54)

0.83

Nulliparas [%; n]

42.6 (214)

44.7 (96)

41.1 (118)

0.48

Gestation at ﬁrst visit [weeks; median (IQR)]

12.1 (1.6)

12.1 (1.4)

12.3 (1.6)

0.90

Planned Pregnancy [%; n]

62.7 (315)

87.9 (189)

43.9 (126)

<0.001

Married [%; n]

49.2 (247)

60.5 (130)

40.8 (117)

<0.001

Current smoker [%; n]

12.9 (65)

3.3 (7)

20.2 (58)

<0.001

Third level educationc

60.1 (272)

77.1 (148)

47.7 (124)

<0.001

Consistent poverty [%; n]d

4.2 (13)

2.1 (3)

6.0 (10)

0.17

History of infertility [%; n]e

14.8 (74)

15.0 (32)

14.6 (42)

0.99

Living in the capital [%; n]

63.5 (319)

59.5 (128)

66.0 (191)

0.33

Irish nativity [%; n]

74.3 (373)

75.3 (162)

73.5 (211)

0.71

a

Prepregnancy deﬁned as before the LMP.

b
c

Pregnancy supplementation deﬁned as after the LMP.

Data for n = 452 for whom third level education deﬁned as third level non-degree qualiﬁcation (e.g. diploma) or higher.

d
e

Data for n = 308, consistent poverty deﬁned as co-occurrence of relative income poverty and depriviation.17

Data for n = 501 for those who reported a history of infertility at the antenatal booking visit.

Table 2 Timing of folic acid (FA) supplement initiation in relation to the
ﬁrst day of the last menstrual period (LMP)
% (n)
≥12 Weeks before LMP

24.9 (109)

8–12 Weeks before LMP

6.2 (27)

4–8 Weeks before LMP

11.7 (51)

0–4 Weeks before LMP

1.1 (5)

0–4 Weeks after LMP

9.2 (40)

4–8 Weeks after LMP

38.2 (167)

≥8 Weeks after LMP
Total

8.7 (38)
100.0 (437)

Of the 502 women, overall the mean RBC folate level
was 1137 (SD 443) nmol/l and median serum folate was
34.6 (IQR 59.5) nmol/l. Table 3 shows median serum folate
and mean RBC folate for the 437 women who reported the
time (in weeks) that they commenced FA relative to their
LMP. Initiating FA supplementation at least four weeks
before the LMP (6 weeks before conception approximately)
was associated with an increased serum folate and an
increased RBC folate compared with initiation 4–8 weeks
after the LMP (P < 0.05 for all). When these ﬁndings were
conﬁned to women who took the recommended over-the-

counter 400 μg FA (low risk women) (Supplementary
Table 2), initiating FA supplementation at least 8 weeks
before the LMP (or ~10 weeks before conception) was associated with an increased serum folate and an increased RBC
folate compared with initiation 4–8 weeks after the LMP.
Table 4 shows the percentage of women with an optimal
RBC folate for the prevention of NTDs ( > 906 nmol/l).21
Of the 437 women reporting the time of FA commencement, 65.7% (n = 330) overall had an optimal RBC folate
level >906 nmol/l. Those who started FA ≥4 weeks before
their LMP (86.4%) had a higher incidence of achieving optimal RBC folate compared to those who started FA 4–8
weeks after their LMP (53.3%) (P < 0.001). The ﬁndings
were similar when this analysis was conﬁned to the 394
women who took 400 μg FA (Supplementary Table 3).
Supplementary Figure 6 shows the positive correlation
between mean RBC folate and the duration of FA supplementation in those women who reported taking 400 μg FA
for ≤52 weeks (r = 0.43, P < 0.001). Supplementary
Figure 7 shows the positive correlation between median
plasma folate and the duration of FA supplementation in
those women who reported taking 400 μg FA for ≤52 weeks
(rho = 0.29, P < 0.001).
Of the 502 women who had blood taken, 392 completed
the retrospective 4-day DH. The median dietary folate was
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Age [years; mean (SD)]
Weight [kg; median (IQR)]
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Table 3 RBC and serum folate (nmol/l) according to timing for all folic acid (FA) supplement initiation (n = 437)
Timing of initiation of FA

RBC folate (mean (SD))

n

P

≥12 Weeks before LMPa

1431.1 (460.2)

109

8–12 Weeks before LMP

1463.4 (385.1)

27

4–8 Weeks before LMP

1199.7 (903.0)

51

0–4 Weeks before LMP

1075.4 (251.0)

5

0–4 Weeks after LMP

966.9 (387.6)

40

4–8 Weeks after LMP

998.4 (361.4)

167

≥8 Weeks after LMP

884.7 (368.5)

38

Serum folate (median (IQR)

n

<0.001

39.0 (14.9)

109

<0.001

<0.001

39.1 (16.7)

27

<0.001

0.03

31.0 (16.0)

51

0.04

0.99

36.1 (22.5)

5

0.12

0.99

28.1 (17.2)

40

0.23

31.0 (16.6)

167

20.2 (22.9)

38

Reference categoryb
0.67

P

Reference categoryb
0.30

Last menstrual period (LMP).

b

Denotes that reference category (4–8 weeks after LMP) used for all comparisons. One-way ANOVA used to assess differences in mean RBC folate

between groups; Kruskall–Wallis and Mann–Whitney U tests used to assess differences in median serum folate between groups.

Table 4 Incidence of optimal RBC folate according to timing of folic acid (FA) supplement initiation for all doses (n = 437)
RBC folate > 906 nmol/l (%, n)

Timing of FA initiation

n

P

≥12 Weeks before LMPa

109

88.1 (96)

<0.001

8–12 Weeks before LMP

27

92.6 (25)

<0.001

4–8 Weeks before LMP

51

78.4 (40)

<0.001

0–4 Weeks before LMP

5

80.0 (4)

Not analysedb

0–4 Weeks after LMP

40

50.0 (20)

4–8 Weeks after LMP

167

53.3 (89)

≥8 Weeks after LMP

38

39.5 (15)

0.71
Reference categoryc
0.12

a

Last menstrual period (LMP).

b

Numbers in 0–4 weeks before LMP category too small for statistical analysis.

c

Denotes that reference category (4–8 weeks after LMP) used for all comparisons.

Cross-tabulation used to assess differences in the percentage of people who achieve optimal RBC folate.

235.2 (IQR 148.2) μg/d. Of these 392 women the median
natural folate was 190.7 (93.4) μg/d, median fortiﬁed FA was
25.6 (79.3) μg/d and median dietary folate equivalents (DFE)
was 255.1 (185.2) μg/d. The mean (SD) fortiﬁed FA is 56.5
(82.6) μg/d which equates to a contribution of 21.3% of the
means (SD) total folate (265.9 (235.2)) and the mean (SD)
natural folate is 209.4 (122.8) μg/d which equates to a contribution of 78.7% of the mean (SD) total folate value. Of these
women, the percentage of women with a daily intake of
<600 μg DFE, which is the reference nutrient intake (RNI)
for folate in early pregnancy as recommended to promote
foetal development by the WHO, was 93.9% (n = 368).22
There was a weak correlation between DFE and maternal
serum folate (rho = 0.21, P = <0.001), and between DFE
and RBC folate (r = 0.14, P=0.006).
There was no difference in DFE according to the time of
FA initiation (P > 0.05 for all) (see Supplementary Tables 4
and 5).

Of these 392 women who competed the 4-day DH,
34.7% (n = 136) were classiﬁed as dietary energy underreporters. These under-reporters were younger, more likely
to be obese and to be unmarried (all P < 0.05) (Data not
shown). Total dietary folate intake, including that derived
from fortiﬁed foods, was higher amongst the plausible
reporters compared with the under-reporters (259.0 (IQR
129) μg/d versus 178.0 (IQR 106) μg/d; P <0.001).
However, after excluding under-reporters, 91.2% of women
(n = 235) were still taking less than the 600 μg DFE recommended by the WHO for early pregnancy.22

Discussion
Main ﬁndings of this study

In a recent updated evidence report and systematic review
for the United States Preventive Services Task Force on FA
supplementation for the prevention of NTDs, limited
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What is already known on this topic

In one study, 144 healthy non-pregnant women aged 19–33
years were given 400 μg FA daily for 24 weeks duration.25
This study took place in Germany where FA food fortiﬁcation is voluntary. After 12 weeks of supplementation, serum
plasma plateaued but RBC folate had not plateaued by the
end of 24 weeks. Serum and RBC folate were measured
using the microbiological assay. The authors suggested that
the minimum recommended duration of FA supplementation before conception should be increased from >4 to >11

weeks. The same group have published on the pharmacokinetics of FA supplementation in healthy women who were
not pregnant.26 In this study, they estimated that the biological half-life is eight weeks, and reported that the increase
in RBC folate concentration depends on the dose of the
supplement and on baseline RBC folate levels. In a further
study of 46 healthy women who were not pregnant, a RBC
folate threshold of >906 nmol/l was reached after an average of 4.2 weeks (SD 3.5) but this required a higher dose of
800 μg FA daily.27 This duration is shorter than that
observed in our study even when all doses (including doses
>400 μg) are included in the analysis, but this may be
explained by different baseline levels of RBC folate.
In a further RCT from Germany, 198 non-pregnant
healthy women who were off supplementation for 2 months
and who were recruited as volunteers, were allocated to
receive either 400 or 800 μg/d of FA.28 Obese women were
excluded. An immunoassay was used to measure RBC folate. Amongst the full cohort, RBC folate at baseline was
deﬁcient in 6.1% and suboptimal in 88%. In this non-obese
group, the percentage of women with suboptimal RBC folate was higher than that observed in our study. After 4 and
8 weeks supplementation, serum and RBC folate levels were
higher in the 800 μg group. Notably, the number of women
with an optimal RBC folate after 4 weeks was 46% in the
800 μg group compared with 31% in the 400 μg group
(P < 0.04), and after 8 weeks was 84% compared with 55%
(P < 0.001). The authors concluded that in the absence of
mandatory folate food fortiﬁcation, a supplement of 400 μg
was insufﬁcient to achieve optimal RBC folate levels within
4–8 weeks which is similar to results from our study which
suggest FA supplementation of 400 μg is needed for 6 weeks
before conception to achieve an optimal RBC folate level.
In a study of 226 women aged 18–35 years presenting for
antenatal care at a mean of 13.7 weeks gestation; of those
who had taken FA 400 μg/d supplementation in the ﬁrst trimester, 19% had started before pregnancy.15 This study
took place in Northern Ireland where FA food fortiﬁcation
is also voluntary. The incidence of optimal RBC folate was
73% in women who started before pregnancy compared
with 47% who started after the sixth week of pregnancy (P
<0.001). RBC folate was measured using the microbiological
assay. These data were not analysed by weeks in assessing
the duration of supplementation or its timing in relation to
conception. Nonetheless, it is consistent with the ﬁndings of
our study as women who took FA preconceptionally were
more likely to have an optimal RBC folate compared to
women who did not take FA preconceptionally.
Total dietary folate intakes observed in the present study
were slightly lower than those observed in other studies
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information was found on the timing of supplementation
and no information on duration was identiﬁed for the prevention of NTDs.23 While our study did not examine NTD
as an outcome, it examined the optimal RBC folate for
NTD prevention. Our study in early pregnancy found that
maternal RBC folate correlated positively with the duration
of FA supplementation and, as result, women who started
FA at least 6 weeks before conception (4 weeks before
LMP) were more likely to achieve the RBC folate concentration associated with optimal NTD prevention compared to
those who started 4–8 weeks after the LMP.
In an analysis based on week of initiation of FA in relation to conception we found that women who started FA
during pregnancy usually started supplementation just before
or after neural tube closure and thus this supplementation,
particularly if started after conception, was unlikely to be
effective in NTD prevention. ‘However, in our study, initiation of FA supplementation was clustered around 4–8
weeks after the LMP because it is usually during this time
interval that women realize they are pregnant and that it is
conﬁrmed by a positive HCG test.24’
It is a concern that this is the point at which the majority
of women commence supplementation with FA given that
just over half of women who commence FA at this time
point achieve an optimal level of RBC folate for NTD
prevention.
Using a detailed dietary questionnaire with up to date
brand information on FA fortiﬁcation, we also found that
only 6.1% of women in early pregnancy were meeting the
WHO recommended intake of >600 μg/d DFE with
energy under-reporters included in the analysis; this ﬁgure
rose to 9.1% when under-reporters were excluded from the
analysis. Maternal dietary folate levels were inadequate in
early pregnancy despite voluntary food fortiﬁcation with
FA. These ﬁndings help explain why the current supplementation and voluntary food fortiﬁcation strategies have
failed to improve rates of NTDs in Europe over the last 25
years.1,7

OPTIMIZATION OF FOLIC ACID SUPPLEMENTATION

What this study adds

To our knowledge, for the ﬁrst time this study provides
detailed information on the dose and the duration of FA
supplementation in pregnancy, with the latter expressed in
weeks which can be timed relative to neural tube closure following a dating ultrasound. While other studies have examined how the timing of FA initiation affects RBC folate,
these previous studies have not provided this detailed (by
week of initiation of FA in relation to the LMP) breakdown
of how time of initiation and dose of FA inﬂuences RBC
folate levels.15. In addition, up to date and detailed information on natural folate and fortiﬁed FA, DFE and total dietary folate, and on maternal folate measurements were
recorded simultaneously in the same cohort of women in
early pregnancy. These data were augmented by clinical and
sociodemographic information which were used to enhance
the strength and integrity of our inferential multivariate
analyses.15
Limitations of this study

The study was undertaken in a country with voluntary FA
food fortiﬁcation, thus the implications of the ﬁndings for
countries with mandatory FA fortiﬁcation require further
study. Participants were recruited at their convenience
because it was not feasible with limited resources to collect
detailed clinical, dietary and supplement details in women
presenting consecutively for antenatal care in a busy maternity hospital. Random selection was also not feasible given
the limited resources.
Maternal serum folate levels are possibly more important
for the closure of the neural tube than RBC folate which
reﬂects storage of folate. There was also a positive relationship between the duration of FA supplementation and

serum folate, however, a cut-off for optimal serum folate
concentration for prevention of NTDs has not been
established.

Conclusions
Based on our ﬁndings, we believe that national and international guidelines need to highlight the importance of
women starting FA at least 6 weeks before conception
(4 weeks before LMP). Women planning a pregnancy should
be advised to start FA at least 6 weeks before trying to conceive if they are to optimize their RBC folate levels. As half
of pregnancies are unplanned, our ﬁndings conﬁrm that
women who could potentially become pregnant should take
a daily supplement of FA. Finally, the low total dietary folate
intake observed in this study despite voluntary FA food fortiﬁcation strengthens the need to implement mandatory FA
fortiﬁcation in European countries.
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